Welcome To Research of the Rockies

ADAGIO-2

CN012-0024 Principal Investigator: Christen Kutz, PhD, PA-C

A Phase 3, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease 

MINDSET 2

CN012-0052 Principal Investigator: Adam Wolff, MD

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease 

AMPLIFI

IMVT-1402-2401 Principal Investigator: Karen Karwa, MD

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

THRIVE

20668A Principal Investigator: Ravi Shah, MD

Interventional, open-label trial, investigating the effectiveness of eptinezumab in participants with migraine and previous inadequate response to CGRP-targeting therapies

ENABLE

TG1101-RMS406 Principal Investigator: Christen Kutz, PhD, PA-C

REal world experieNce with BRIUMVI® (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study 

Please email Aspen Beck at abeck@coneuroclinic.com for additional information.